Completion of enrolment in PARTNER clinical trial, comparing MagnetOs to autograft First patient treated with MagnetOs Flex Matrix 10,000 patients now treated with MagnetOs worldwide Kuros Biosciences (“Kuros” or the […]
Autor: Firma Kuros Biosciences
Kuros Biosciences reports results for the first six months of 2022
Financial highlights CHF 29.4 million cash & cash equivalents, trade and other receivables as of June 30, 2022 Product sales increased by 58% to CHF 5.7 million Operational highlights FDA […]
Annual General Meeting of Kuros Biosciences approves all resolutions
. Kuros Biosciences (SIX:KURN) today announced that its Annual General Meeting approved all resolutions proposed by the Board of Directors. The Annual General Meeting approved the Annual Report, the Annual […]
Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial
Fusion rate 78%, vs 42% for autograft and 55-71% for other synthetic bone grafts First of five planned randomized controlled trials for MagnetOs Data will support product approvals at hospitals […]
Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.
Soft, moldable formulation that is ready to use with no need for thawing or mixing Becomes third commercial MagnetOs product Kuros Biosciences (“Kuros” or the “Company”), a leader in next […]
Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft
. Medical devices Q1 2022 sales accelerate, rising 102% over Q1 2021 FDA cleared MagnetOs Granules for expanded indications in spine and MagnetOs Flex Matrix as bone void filler in […]
Kuros Biosciences’s MagnetOs Flex Matrix Cleared by FDA for Spinal Indications
Clearance as a bone void filler for use in the posterolateral spine Third FDA clearance for MagnetOs in the last 7 months Product provides opportunity to de-risk U.S. commercialization […]
Kuros Biosciences’s MagnetOs Granules cleared by FDA for expanded spinal indications
Rare clearance for bone graft for standalone use in spine based on human clinical data Clearance attained with evidence from Level 1 randomized controlled trial Positions MagnetOs above most other […]
Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures
. Phase II data published in peer-reviewed Journal of Bone and Joint Surgery Healing rate at six months post-surgery was higher than standard of care Significantly de-risks development of Fibrin-PTH […]
Kuros Biosciences reports continued increase in MagnetOs U.S. sales
MagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020 Kuros expanding MagnetOs range to increase perioperative solutions for surgeons Kuros Biosciences (“Kuros” or the “Company”), a leader […]